Last update Oct. 9, 2016



Safe substance and/or breastfeeding is the best option.

Antihistamine for topical use both on nose and eye.

Plasma concentrations reached are very low and, according to the manufacturer, it is excreted into breastmilk in clinically non-significant amount at 0.3 to 0.6% of maternal dose: 1.5 to 3 micrograms.

As in most ophthalmic and nasal topically used preparations, the tiny dose and poor levels in the blood, render it compatible with breastfeeding.


We do not have alternatives for C26H29FN2O2 since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

C26H29FN2O2 is Levocabastine Hydrochloride in Molecular formula.

Is written in other languages:


Variable Value Unit
Oral Bioavail. Oft 30-60. Nas 60-80 %
Molecular weight 457 daltons
Protein Binding 55 %
VD 1.2 l/Kg
Tmax 2 hours
35 - 40 hours


  1. AEMPS. Levocabastina Nasal. Ficha técnica. 2016 Full text (in our servers)
  2. AEMPS. Levocabastina oftálmica. Ficha técnica. 2016 Full text (in our servers)
  3. J & J. Levocabastine. Drug Summary. 2010 Full text (in our servers)

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM